Online inquiry

Murine Leukaemia Virus-Like Particle (MLVLP) Development Service

Q: How does MLVLP delivery efficiency compare to non-viral methods, such as Lipid Nanoparticles (LNPs)?

MLVLPs have a key edge—active endosomal escape via native viral entry to release payload into cytoplasm efficiently. LNPs rely on passive uptake and complex lipid formulations for endosome destabilization, with variable results. We can share comparative data against leading LNP systems.

Q: Can your custom MLVLPs deliver both mRNA and large therapeutic proteins?

Yes. We optimize the VLP core for two payloads: mRNA (via Aptamer/ABP system for efficient loading) and proteins (PT-VLPs, encapsulating large functional proteins like Transcription Factors). Share your payload for optimal VLP configuration recommendations.

Introduction Murine Leukemia Virus-Like Particle (MLVLP) Workflow What We Can Offer FAQ

Introduction

Murine Leukemia Virus-Like Particles (MLVLPs) are safe retroviral-like nanoparticles without genetic material. They use retroviral core structures for transport, enable targeted delivery and endosomal escape, and act as carriers for transient gene expression or direct protein transduction.

Creative Biolabs leverages expertise to turn this tech into a customizable platform. Its service offers proprietary MLV-VLP engineering, aptamer-mediated loading, and robust non-integrating vectors with specific tropism, solving delivery bottlenecks for safe, efficient therapeutic delivery.

Discover How We Can Help - Request a Consultation

Murine Leukemia Virus-Like Particle (MLVLP) Development Service

Mechanism

The MLVLP mechanism is based on two key features that distinguish it from passive delivery systems:

Structural Core and Endosomal Escape: The VLP is assembled from the highly conserved MLV Gag protein core. This structure retains the essential viral machinery needed for membrane fusion and uncoating inside the cell. When the VLP is internalized via endocytosis, it actively fuses with the endosomal membrane, releasing the payload directly into the cytoplasm before it can be trafficked to the lysosome for degradation.
Aptamer-Mediated Cargo Loading: MLVLPs achieve highly specific cargo encapsulation using the RNA Aptamer/Aptamer-Binding Protein (ABP) system (e.g., MS2 RNA aptamer/MS2 coat protein or PP7/PCP). The therapeutic mRNA is engineered to contain the aptamer sequence, while the corresponding ABP is co-expressed within the MLV core. This high-affinity interaction ensures the mRNA is selectively packaged into the forming particle, maximizing cargo stability and load efficiency.

Application: Therapeutic Modalities

Advanced Cell Therapy and Reprogramming: Delivering Transcription Factors (as protein or via mRNA) for safe, non-genomic T-cell, B-cell, and Stem Cell reprogramming, enabling next-generation ex vivo therapies.
Targeted Oncology: Utilizing the custom targeting capability to deliver highly potent cytotoxic payloads (e.g., toxic proteins or specific siRNAs) only to cancer cells, reducing systemic toxicity and maximizing the therapeutic window.
Next-Generation mRNA Vaccines: Delivering antigen-encoding mRNA directly and efficiently to professional Antigen-Presenting Cells (APCs), promoting superior immunogenicity and both strong humoral and cellular immune responses.
Protein Replacement Therapy: Enabling the transient, high-level expression of functional enzymes and growth factors for genetic diseases or regenerative medicine applications.

Advantages

Safety: Non-replicating, non-integrating, significantly reducing safety concerns over traditional retroviral systems.
Targeting: Superior specificity via custom envelope engineering, enabling delivery to previously inaccessible or hard-to-target cell populations.
Efficiency: Active endosomal escape ensures maximal payload delivery to the cytoplasm, dramatically increasing functional activity compared to passive uptake mechanisms.
Versatility: Capable of packaging diverse payloads, including mRNA, small interfering RNA (siRNA), and large, functional proteins

Workflow

Our systematic workflow is designed to move your project rapidly from concept to high-quality, clinical-grade MLVLPs. The process is fully documented and transparent, ideal for clients requiring rigorous quality control and data integrity.

Required Starting Materials

Target Cell Receptor/Ligand Information: Detailed biological information on the surface markers or receptors of the desired target cell type.
Sequence of Therapeutic Payload: The sequence of the mRNA, gene, or protein to be loaded.
Target Expression Level/Titer: Specific requirements for in vitro or in vivo VLP titer and expected cellular expression levels.

Target Receptor Analysis & Envelope Engineering

Analyze your target receptor and design optimal envelope (Env) modifications, including selecting and cloning pseudotyping proteins or custom targeting ligands, and co-expressing them with the MLV Gag structural core; establish an optimized VLP producer cell line.

Payload Construct Design & Optimization

Design nucleic acid constructs (e.g., therapeutic mRNA) incorporating specific RNA aptamer sequences (e.g., MS2, PP7) that bind with high affinity to the Aptamer-Binding Protein (ABP) in the MLVLP core; obtain a high-stability, VLP-compatible cargo construct.

VLP Production & Purification

Initiate large-scale VLP production in stable mammalian producer cells, followed by multi-step purification (ultracentrifugation, chromatography) to isolate high-purity particles; obtain a concentrated, high-purity VLP preparation.

Quality Control & Titer Titration

Conduct comprehensive quality tests, including analysis of VLP size, morphology (EM), protein content (ELISA/Western Blot), and functional titer determination; generate batch release data confirming VLP quality and dosage.

Delivery Validation & Efficacy Testing

Test final formulations in vitro (in vivo optional) to confirm targeted delivery, endosomal escape efficiency, and functional expression of the therapeutic payload in specified target cells; obtain empirical proof-of-concept data for lead VLP candidates.

Final Deliverables

Final VLP Formulation Report: Detailed documentation covering VLP composition, production parameters, and stability data.
QC Data Package: Comprehensive quality control results, including functional titer, purity analysis, and Endotoxin/Sterility testing.
In Vitro Efficacy Report: Data confirming targeted cell uptake, endosomal escape efficiency, and therapeutic payload activity.

Estimated Timeframe: The typical timeframe for this service ranges from 8 to 14 weeks, depending on the complexity of the envelope customization, the optimization required for the payload, and the number of post-production QC assays requested.

What We Can Offer

As the industry leader in custom MLVLP manufacturing, Creative Biolabs provides an integrated suite of services designed for maximum efficiency, quality, and scalability, regardless of your project phase. We provide end-to-end support for your Murine Leukemia Virus-Like Particle (MLVLP) Development Service.

Customization and Optimization

We specialize in optimizing the codon usage of your gene of interest to facilitate maximum expression in our selected MLVLP producer cell lines and can run the production process in batch, fed-batch, or continuous mode to suit your yield and purity needs.

Quality Assurance and Compliance

Our quality system is based on Quality-by-Design (QbD) principles, incorporating robust checks on strain origin and stability. We guarantee strict aseptic verification procedures throughout the entire fermentation and purification process to ensure GMP readiness.

Scalability and Production Capacity

We offer one-stop production from laboratory scale to pilot scale to large scale, utilizing industrial fermentation tanks with a total capability of over 100,000 liters. This massive capacity ensures a seamless transition to commercial volumes.

Product Quality Guarantee

We take precautions and strictly follow the Hazard Analysis Critical Control Point (HACCP) approach and the basic principles of Good Manufacturing Practice (GMP). High-standard quality control tools are consistently used to quantify and evaluate the final MLVLP product quality and stability.

Cell Bank Stability

We guarantee the stability of strains in cell banks and large-scale fermentations (including pre-cultivation), ensuring reproducible and reliable VLP production across all scales.

Experience the Creative Biolabs Advantage - Get a Quote Today

Customer Reviews

Non-integrating Nature "The non-integrating nature of these MLV-VLPs is a game-changer. We shifted from lentiviral vectors because of safety concerns, and the stability of Creative Biolabs' particles is far superior. A real time-saver in preclinical assessment, allowing us to rapidly move to efficacy trials."

— Amy Smith, [1 Month Ago]
mRNA Vaccine Delivery "Using Creative Biolabs' Custom MLVLP Development Service in our research has significantly improved the efficiency of our mRNA vaccine candidate delivery into Dendritic Cells. The high transient expression levels we achieved are unmatched by standard LNPs, driving a potent immune response."

— Raj Bhanu, [2 Weeks Ago]
Custom Targeting "The ability to customize the VLP envelope for specific receptor targeting was essential for our oncology project. The final VLP formulation was incredibly pure and maintained high titer, solving our previous low-specificity problem and focusing our cytotoxic payload exactly where it needed to be."

— Joe Doyle, [3 Months Ago]

FAQ

What are the primary safety advantages of MLVLPs over standard viral vectors, like Lentivirus?

MLVLPs are safer as they are non-integrating and replication-defective, acting only as a transient transport shell. This eliminates insertional mutagenesis risk, suiting applications like therapeutic T-cell and stem cell reprogramming. Discuss your regulatory needs with our team for safety priorities.

How does MLVLP delivery efficiency compare to non-viral methods, such as Lipid Nanoparticles (LNPs)?

MLVLPs have a key edge—active endosomal escape via native viral entry to release payload into cytoplasm efficiently. LNPs rely on passive uptake and complex lipid formulations for endosome destabilization, with variable results. We can share comparative data against leading LNP systems.

Can your custom MLVLPs deliver both mRNA and large therapeutic proteins?

Yes. We optimize the VLP core for two payloads: mRNA (via Aptamer/ABP system for efficient loading) and proteins (PT-VLPs, encapsulating large functional proteins like Transcription Factors). Share your payload for optimal VLP configuration recommendations.

How does Creative Biolabs achieve targeted delivery for my specific cell type?

We engineer the VLP exterior—replace native envelope with custom Env glycoproteins or targeting ligands. These bind only to receptors overexpressed on target cells (e.g., tumor markers, immune cell receptors), maximizing efficacy and minimizing off-target effects in vivo.

What is the minimum project size, and is the platform scalable for clinical trials?

We support small academic research to large clinical-grade production. Our MLVLP production uses stable mammalian producer cell lines, enabling consistent, high-titer GMP-compatible scale-up. Contact us to discuss your scale and get a detailed production plan.

Creative Biolabs is committed to accelerating your drug discovery and development pipeline by providing the most advanced, safe, and scalable Custom Murine Leukemia Virus-Like Particle (MLVLP) Development Service. Our expertise ensures your therapeutic payloads reach their target with unmatched precision.

Contact Our Team for More Information and to Discuss Your Project

Hot IVT Vectors

Cat. No	Product Name	Promoter
GTVCR-WQ001MR	IVTScrip™ pT7-mRNA-EGFP Vector	T7
GTVCR-WQ002MR	IVTScrip™ pT7-VEE-mRNA-EGFP Vector	T7
GTVCR-WQ003MR	IVTScrip™ pT7-VEE-mRNA-FLuc Vector	T7
GTVCR-WQ004MR	IVTScrip™ pT7-VEE-mRNA-mCherry Vector	T7

Hot IVTScrip™ mRNA Transcript

Cat. No	Product Name	Type
GTTS-WQ001MR	IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A))	Reporter
GTTS-WQ002MR	IVTScrip™ mRNA-EGFP, 5-Methoxy-U modified (Cap 1, 30 nt-poly(A))	Reporter
GTTS-WQ003MR	IVTScrip™ mRNA-EGFP, 5-Methoxy-U, Cyanine 5-U modified (Cap 1, 30 nt-poly(A))	Reporter
GTTS-WQ004MR	IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A))	Reporter

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.